Development PipelineLadiratuzumab vedotin

an investigational antibody–drug conjugate directed to LIV-1

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNLVA-002/KEYNOTE-721: Locally advanced or metastatic triple-negative breast cancer​​ (LV + pembrolizumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGNLVA-005: Locally advanced or metastatic solid tumors expressing LIV-1

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of ladiratuzumab vedotin and ongoing clinical trials

View/Download

Detailed information about ladiratuzumab vedotin clinical trials

View in Interactive Pipeline

Related Links

List of Congress
Presentations

Medical Information
Request Form

Back to Pipeline